Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin

Liver Transplantation

Volumn 7, Issue 3, 2001, Pages 181-190

  Gopal, Deepak V ^a,b,c,d   Rabkin, John M ^a,b,c,d   Berk, Brian S ^a,b,c,d   Corless, Christopher L ^a,b,c,d   Chou, Sunwen ^a,b,c,d   Olyaei, Ali ^a,b,c,d   Orloff, Susan L ^a,b,c,d   Rosen, Hugo R ^a,b,c,d  

^a Gastroenterology and Hepatology Division   (United States)

^b Division of Infectious Diseases   (United States)

^c Department of Surgery and Liver Transplantation ^*  (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CONSENSUS INTERFERON; CYCLOSPORIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERFERON; RIBAVIRIN; TACROLIMUS; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLAMMATION; INTRAHEPATIC CHOLESTASIS; LEUKOPENIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MALE; MORTALITY; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS RESISTANCE;

EID: 0035087366     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2001.22447     Document Type: Article

References (38)

1. Graft loss following liver transplantation in patients with chronic hepatitis C
2. Long-term outcome of hepatitis C infection after liver transplantation
3. Retransplantation for hepatitis C: Implications of different policies
4. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury
5. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes
6. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
7. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post transplantation
8. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients
9. Interferon alpha therapy for hepatitis C virus infection after liver transplantation
10. Alpha-interferon for acute hepatitis C in liver transplant patients
11. New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin
12. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
13. The utility of protocol biopsies post liver transplant
14. Histological grading and staging of chronic hepatitis
15. Clinical and histologic patterns in early graft failure due to recurrent hepatitis C infection after liver transplantation
16. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation
17. Viral hepatitis in the liver transplant recipient
18. Classification of hepatitis C into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
19. Quantification of hepatitis C virus by TaqMan PCR: Comparison with HCV Amplicor monitor assay
20. Hepatitis C: The clinical spectrum of disease
21. Recurrent hepatitis C after liver transplantation
22. Hepatitis C virus infection in patients undergoing liver retransplantation
23. Quality of life in long-term survivors after liver transplantation: Impact of recurrent viral hepatitis C virus hepatitis
24. Recurrent hepatitis C after liver transplantation: Clinical and therapeutic issues
25. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial
26. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation
27. Hepatitis C virus recurrence after liver transplantation
28. Poor prognosis of patients retransplanted for recurrent liver disease due to hepatitis C virus
29. A pilot study of ribavirin therapy for hepatitis C virus infection after liver transplantation
30. Ribavirin therapy for hepatitis C infection following liver transplantation
31. Pilot study of the combination of interferon alpha and ribavirin as therapy of recurrent hepatitis C after transplantation
32. Successful rescue of severe recurrent hepatitis C with interferon and ribavirin in a liver transplant patient
33. Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination
34. Filgastrim (r-metHuG-CSF): The first 10 years
35. Treatment of intra-abdominal infection with granulocyte colony-stimulating factor
36. Randomized, placebo-controlled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients
37. Anemia and erythropoietin levels in recipients of solid organ transplants. The Multi-Organ Transplant Group
38. Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C